Overview

A Pilot Trial of AVD and Brentuximab Vedotin (SGN-35) in the Treatment of Stage III-IV HIV-associated Hodgkin Lymphoma

Status:
Active, not recruiting

Trial end date:
2021-10-16

Target enrollment:

Participant gender:

Summary

This phase II trial studies the side effects and the best dose of brentuximab vedotin and combination chemotherapy work in treating patients with stage III-IV human immunodeficiency virus (HIV)-associated Hodgkin lymphoma. Monoclonal antibodies, such as brentuximab vedotin, can block cancer growth by finding cancer cells and causing them to die. Drugs used in chemotherapy, such as doxorubicin hydrochloride, vinblastine sulfate, and dacarbazine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving brentuximab vedotin together with combination chemotherapy may kill more cancer cells.

Phase:

Phase 2

Details

Lead Sponsor:

The Lymphoma Academic Research Organisation

Treatments:

Antibodies
Antibodies, Monoclonal
Brentuximab Vedotin
Dacarbazine
Doxorubicin
Immunoconjugates
Immunoglobulins
Liposomal doxorubicin
Vinblastine